profit from every $100 of sales.
$0$100
AN2 Therapeutics
$4.00+0.00% today
+250.9% in 1 year
1-year low $1.031-year high $6.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What AN2 Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$35.2 million of profit last year.
SalesProfit
AN2 Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AN2 Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads AN2 Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -42 | -70 | -55 | -38 | |
| -42 | -70 | -55 | -38 | |
| -41 | -65 | -51 | -35 | |
| -2.79 | -2.74 | -1.72 | -1.16 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 103 | 139 | 92 | 62 |
| Cash | 27 | 16 | 21 | 20 |
| Total debt | 0 | 0 | – | – |
| Total liabilities | 7 | 14 | 10 | 9 |
| 95 | 125 | 82 | 53 | |
| 15 | 24 | 30 | 30 | |
| -35.0% | -44.1% | -52.7% | -56.7% | |
| -42.9% | -51.9% | -62.7% | -66.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -33 | -53 | -49 | -30 | |
| – | – | – | – | |
| -33 | -53 | -49 | -30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 8 | 8 | 6 |
Valuation
- –
- –
- –
- 2.5×
- –
- –
- –
- -19.8%
- -23.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -71.6%
- -51.7%
- -55.0%
- -56.8%
- -71.6%
- –
Growth
- –
- –
- +39.4%
- –
- +12.7%
Financial health
- -0.5×
- 0.00
- 0.0%
- –
- 6.87
- 6.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 948
Bottom 21%of 871
Bottom 4%of 985
What analysts expect
- Average price target
- $7.75
- Range
- $2.00 – $22.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.29 | -0.23 | −26.1% |
| Mar 17, 2026 | -0.29 | -0.24 | −20.8% |
| Nov 12, 2025 | -0.31 | -0.23 | −34.8% |
| Aug 12, 2025 | -0.21 | -0.31 | +32.3% |
| May 13, 2025 | -0.35 | -0.26 | −34.6% |
| Mar 25, 2025 | -0.25 | -0.25 | +0.0% |
| Nov 13, 2024 | -0.43 | -0.37 | −16.2% |
| Aug 13, 2024 | -0.48 | -0.63 | +23.8% |
News
Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha · Nov 6, 2026Cognition Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 29, 2026LENZ Therapeutics GAAP EPS of -$0.99 misses by $0.04, revenue of $3.38M misses by $0.82MSeeking Alpha · Oct 28, 2026Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumYahoo Finance · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
46No pass
Philip Fisher
33No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
26No pass
Questions about AN2 Therapeutics
Is AN2 Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AN2 Therapeutics AI analysis
What does AN2 Therapeutics do?
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is in Biotechnology.
Does AN2 Therapeutics pay a dividend?
No. AN2 Therapeutics does not pay a dividend at the moment.
Is AN2 Therapeutics stock halal?
No. AN2 Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 38% of its market value, at or above the 33% limit. How we check
How has AN2 Therapeutics stock done over the past year?
Up 250.9% over the past twelve months, to $4.00. It traded between $1.03 and $6.28 and is 36.3% below its high.
Who are AN2 Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with AN2 Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.